Bank of America Cuts Hims & Hers Health (NYSE:HIMS) Price Target to $25.00

Hims & Hers Health (NYSE:HIMS) had its price target reduced by equities research analysts at Bank of America from $28.00 to $25.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Bank of America‘s price objective would indicate a potential upside of 5.49% from the company’s current price.

HIMS has been the topic of a number of other research reports. Evercore set a $24.00 price target on shares of Hims & Hers Health in a report on Tuesday, February 24th. UBS Group set a $23.00 price objective on shares of Hims & Hers Health in a research report on Friday. Citigroup boosted their price objective on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. Jefferies Financial Group set a $24.50 price objective on shares of Hims & Hers Health in a research report on Tuesday, May 12th. Finally, Truist Financial boosted their price objective on shares of Hims & Hers Health from $18.00 to $23.00 and gave the company a “hold” rating in a research report on Friday. Four investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $28.70.

Hims & Hers Health Trading Down 0.2%

Shares of HIMS stock traded down $0.05 during trading hours on Tuesday, reaching $23.70. 10,354,683 shares of the stock traded hands, compared to its average volume of 32,232,939. Hims & Hers Health has a 1-year low of $13.74 and a 1-year high of $70.43. The business has a fifty day moving average price of $24.03 and a 200 day moving average price of $27.85. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The firm has a market capitalization of $5.40 billion, a PE ratio of -263.33, a PEG ratio of 46.09 and a beta of 2.43.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The firm had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. During the same quarter in the prior year, the firm earned $0.20 EPS. The firm’s revenue was up 3.8% compared to the same quarter last year. On average, equities research analysts forecast that Hims & Hers Health will post 0.04 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 9,463 shares of the business’s stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $30.00, for a total value of $283,890.00. Following the completion of the sale, the insider directly owned 299,368 shares of the company’s stock, valued at $8,981,040. The trade was a 3.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 7,950 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $23.64, for a total transaction of $187,938.00. Following the completion of the sale, the chief financial officer directly owned 262,954 shares of the company’s stock, valued at $6,216,232.56. This represents a 2.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 212,807 shares of company stock valued at $5,473,644. 11.76% of the stock is currently owned by insiders.

Institutional Trading of Hims & Hers Health

Several large investors have recently made changes to their positions in HIMS. Flagship Harbor Advisors LLC bought a new stake in shares of Hims & Hers Health during the 4th quarter worth about $28,000. Binnacle Investments Inc bought a new position in shares of Hims & Hers Health in the 3rd quarter valued at approximately $28,000. Bogart Wealth LLC raised its stake in shares of Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 632 shares in the last quarter. Geneos Wealth Management Inc. bought a new position in shares of Hims & Hers Health in the 1st quarter valued at approximately $30,000. Finally, Greenline Wealth Management LLC bought a new position in shares of Hims & Hers Health in the 4th quarter valued at approximately $36,000. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.